In the treatment of autoimmune diseases, intravenous Igs (IVIg) are assumed to modulate immune cells through the binding of surface receptors. IVIg act upon definite human B cell populations to modulate Ig repertoire, and such modulation might proceed through intracellular signaling. However, the heterogeneity of human B cell populations complicates investigations of the intracellular pathways involved in IVIg-induced B cell modulation. The aim of this study was to establish a model allowing the screening of IVIg signal transduction in human B cell lines and to attempt transposing observations made in cell lines to normal human B lymphocytes. Nine human B cell lines were treated with IVIg with the goal of selecting the most suitable model for human B lymphocytes. The IgG 1 DB cell line, whose response was similar to that of human B lymphocytes, showed reduced IVIg modulation following addition of PD98059, an inhibitor of extracellular signal-regulated protein kinase 1/2 (ERK1/2). The IVIg-induced ERK1/2 phosphorylation was indeed proportional to the dosage of monomeric IVIg used when tested on DB cells as well as Pfeiffer cells, another IgG 1 cell line. In addition, two other intermediates, Grb2-associated binder 1 (Gab1) and Akt, showed increased phosphorylation in IVIg-treated DB cells. IVIg induction of ERK1/2 phosphorylation was finally observed in peripheral human B lymphocytes, specifically within the IgG 1 B cell population. In conclusion, IVIg immunomodulation of human B cells can thus be linked to intracellular transduction pathways involving the phosphorylation of ERK1/2, which in combination with Gab1 and Akt, may be related to B cell antigen receptor signaling.
Introduction
Intravenous Igs (IVIg) are used in the treatment of many inflammatory and autoimmune disorders [reviewed in ref. (1, 2) ]. IVIg's anti-inflammatory effects could be mediated by their Fc or F(ab#) 2 fragments (3). The beneficial effects of IVIg in many autoimmune diseases are dependent on its interaction with Fc receptors [reviewed in ref. (4) ], which play central roles in the regulation of immune responses (5) . In many cases, IVIg treatment results in the suppression of pathologic autoimmune antibodies in the patient's serum for prolonged periods of time (6) . IVIg treatment has also been linked to the re-establishment of homeostasis among natural antibodies in the patient's serum (7) . Anti-idiotypic antibodies, related to anti-F(ab#) 2 fragments, found in IVIg (8) are reactive with pathologic auto-antibodies, and many authors have postulated that these antibodies could modulate autoreactive B cells and restore homeostasis in patients with autoimmune diseases [reviewed in ref. (9) (10) (11) ]. Indeed, anti-DNA antiidiotypic antibodies purified from IVIg were successfully used to treat NZB/W mice, a murine model for human systemic lupus erythematosus (12) . Consequently, the re-establishment of a normal idiotypic network is one of the mechanisms put forward to explain the long-term effects of IVIg (13, 14) .
The injection of normal murine IgG induces the deletion of pre-B cells within the bone marrow or the selective activation of splenic B cells (7, 10, 15) . In humans, links between antiidiotypic antibodies in IVIg and B cells expressing V H 3-23 and V H 3-30/3-30.5 in Kawasaki disease (16) , systemic lupus erythematosus and autoimmune thrombocytopenia (17, 18) were highlighted using phage display technology. The specific link between these V H 3-23 and 3-30/3-30.5 and the repertoire of patients suggests that IVIg interact in vivo with B cells expressing these idiotypes on their B cell antigen receptor (BCR) (16) .
Binding of the BCR is central to B lymphocyte development; signal transduction through the BCR regulates the survival, proliferation and maturation of B cells [reviewed in ref. (19) ]. BCR stimulation induces a cascade of events beginning with the phosphorylation of the immunoreceptor tyrosine-based activation motifs in the cytoplasmic tail of CD79a/CD79b by the Src-family phosphotyrosine kinase Lyn and the tyrosine kinase Syk. These activated kinases induce the formation of membrane-associated ligands including phosphotyrosine, phosphatidylinositol (3, 4, 5) -triphosphate (PI-3,4,5,-P 3 ) and diacylglycerol that, respectively, bind to proteins with Src-homology-2, pleckstrin-homology and C1 domains. At this step, Grb2-associated binder 1 (Gab1) can act as an amplifier of BCR signaling (20) . Phosphorylation of its tyrosines 307, 373 and 407 modulates Gab1 association to phospholipase Cc while that of tyrosine 627 and 659 is linked to the activation of the protein tyrosine phosphatase Src homology 2-domain-containing protein tyrosine phosphatase (SHP)-2 (21, 22) . All these interactions promote the firing of multiple signals linking the BCR to the activation of kinases such as the Akt/protein kinase B and to additional signaling pathways such as extracellular signal-regulated protein kinase (ERK) and mitogen-activated protein kinases (MAPK) (23, 24) .
The expression of BCR on B cells varies as a function of their developmental and differentiation stages (25) (26, 27) . We have previously showed that naive human B cells treated in vitro with IVIg were induced to reshape their repertoire by increasing the secretion of IgG specific to DNA and human IgG F(ab#) 2 fragments (28), suggesting again that IVIg can specifically target the BCR. Several human B cell lines are blocked at differentiation stages characterized by the definite expression of BCR, ranging from precursor B cells to plasma cells. Among these, the pre-B acute lymphoblastic leukemia cell line SUP-B15 and the multiple myeloma cell line RPMI-8226 do not express surface BCR, while the diffuse large B cell lymphoma RL and DB cell lines only express IgM or IgG, respectively. As for the Burkitt's lymphoma cell lines Daudi, Namalwa, Raji, Ramos and SKW6.4, they simultaneously express IgD and IgM, although at variable levels (29, 30) .
In this study, we established a B cell line model to investigate IVIg intracellular signaling in human B lymphocytes and better understand how IVIg can modulate the in vitro proliferation and/or differentiation of both naive and memory B cells.
Materials and methods

Human peripheral B cells
This study has been reviewed and approved by Hé maQué bec Research Ethics Committee. Samples were obtained from healthy individuals after informed consent. Peripheral blood leukocytes recovered from filters or leucoreduction systems were used to prepare PBMC by density centrifugation over Ficoll-Paque (GE Life Sciences, Piscataway, NJ, USA), as previously described (31, 32) . B cells were purified from PBMC using the StemSep CD19 mixture, according to the manufacturer's instructions (Stem Cell Technologies, Vancouver, Canada). CD27
+ and CD27 À B cells were sorted using an EpicsCoulter (Beckman Coulter, Burlington, Canada). Purified, sorted and cultured B cells were always >96% CD19 + . B cells were cultured with gamma-irradiated, CD154-expressing L4.5 cells (33) or CD154 soluble membranes (34) in the presence of 50 U ml À1 IL-2, 25 U ml À1 IL-10 (PeproTech, Rocky Hill, NJ, USA) and/or 100 U ml À1 IL-4 (R&D Systems, Minneapolis, MN, USA), as previously described (35, 36) . High stimulation corresponded to a ratio of three B cells per CD154
+ L cells or 5000 B cells ll À1 of membranes, and low stimulation corresponded to 25 B cells per CD154
+ cell in the presence of IL-2, IL-4 and IL-10. IVIg treatment was done as previously described (28) .
Human B cell lines
All human B cell lines listed in Table 1 , as well as Pfeiffer cells, were obtained from the American Type Culture Collection (Rockville, MD, USA). All cells were cultured following the manufacturer's instructions and were mycoplasma free. B cell lines were treated as indicated, with various preparations of human IgG or controls.
IVIg and human IgG
IVIg (Gamunex TM ) (37) containing 100 mg ml À1 IgG in 0.2 M glycine and intramuscular Ig (IMIg; GammaSTAN) containing 150 mg ml À1 IgG in 0.3 M glycine were obtained from Bayer Inc. (Toronto, Ontario, Canada). BSA (Cohn fraction V, Sigma, St Louis, MO, USA) was used, when indicated, as control for protein content. IVIg and BSA were dialyzed against 10 mM potassium/sodium phosphate containing 136 mM NaCl (PBS, Invitrogen, Burlington, Ontario, Canada) and 40 mM glycine, pH 4.5 (Sigma). IMIg was dialyzed against the same buffer adjusted to pH 7.1. IgG content in dialyzed IVIg was mainly monomeric (96-98%) and the final concentration was ;100 mg ml À1 , while IMIg contained 21% IgG aggregates and its final concentration ;155 mg ml À1 , as determined on an automated Ä KTA TM FPLC TM System (GE Healthcare Bio-Sciences Inc.) using Unicorn 4.12 version 4.0 software.
Human B cells were incubated as indicated in the presence of IVIg, IMIg or BSA at various concentrations ranging from 0.05 to 20 mg ml À1 for 3-14 days. Polyclonal IgG F(ab#) 2 fragments from goat anti-human IgG (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) were used for BCR cross-linking, as reported elsewhere (38) . Aggregated human IgGs were prepared using purified human IgG (Jackson ImmunoResearch Laboratories, Inc.) and IVIg heated at 63°C for 25 min and then centrifuged (30 0003 g, 20 min, 4°C) (39) . Purity and aggregate content were evaluated by fast protein liquid chromatography (FPLC), as described above. Cell counts and viability were evaluated in triplicate by Trypan Blue dye exclusion on the indicated days.
Flow cytometry analysis
Cells were analyzed using peridinin chlorophyll protein (PerCP)-cyanin 5.5-conjugated anti-CD19; allophycocyaninconjugated anti-CD19 or anti-CD32; PE-conjugated anti-CD27, anti-CD40 (Beckman Coulter, Fullerton, CA, USA), anti-CD45, anti-CD126, anti-CD138 or anti-IgD and FITCconjugated anti-CD20, anti-CD27, anti-CD72 or anti-IgG. PerCP-cyanin 5.5-, allophycocyanin-, PE-and FITC-conjugated isotype controls were used in quadruple or triple staining procedures. Unless indicated, all antibodies were IgG 1 mouse mAbs obtained from BD Biosciences (Mountain View, CA, USA). IgM staining was done using FITC-conjugated polyclonal goat anti-human IgM and an isotype control from Jackson ImmunoResearch Laboratories, Inc. All stainings were done as previously described (31) . Data acquisition was done by gating >10 000 events on a FACSCalibur flow cytometer and the CellQuest Pro software and analysis was done using FCS express II (De Novo Software, Thornhill, Ontario, Canada).
Intracellular phosphorylation of Akt, ERK1/2, p38MAPK, stress-activated protein kinases (SAPK)/Jun N-terminal kinase (JNK) and tyrosine protein was determined using control-and IVIg-treated DB cells. Cells were washed with PBS containing 2% BSA and 0.01% NaN 3 prior to fixation with 2% PFA, then permeabilized using cold methanol and kept at À20°C until analysis. Alexa-488-conjugated antibodies specific for ERK1/2 (thr202/tyr204), p38MAPK (thr180/ tyr182) and phosphotyrosines and Alexa-647-conjugated antibodies specific for Akt (ser 473) and SAPK/JNK (thr183/ tyr185) were from Cell Signalling Technology, Inc. (Danvers, MA, USA). All antibodies were mouse IgG 1 except anti-Akt, which was a rabbit mAb.
IgG and IgM secretion rates
At the end of the culture period, cells were extensively washed five times with PBS and seeded at 1 3 10 6 cells ml À1 in IMDM medium without serum or additives. The IgG and IgM contents of the last washing supernatants were always negligible. Supernatants were collected after 22-24 h and IgG and IgM concentrations were determined by ELISA (35) .
Protein kinase inhibitors
The 4-amino-5-(4-methylphenyl)-7-(t-butyl) pyrazolo [3,4-D] pyrimidine (PP1), 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo [3,4-D] pyrimidine (PP2) and a negative control for both PP1 and PP2 (4-amino-7-phenylpyrazol [3,4- (40) were kindly provided by Donald Branch from the Canadian Blood Services. Wortmannin and LY924002 (Cedarlane Laboratories Ltd, Horby, Ontario, Canada), deguelin, hydralazine, PD98059, SB203580 and U0126 ethanolate (Sigma), as well as 2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide (SU6656) and piceatannol (EMD Biosciences/Calbiochem, San Diego, CA, USA), were used at non-toxic concentrations as determined by doseresponse assays. PP1, PP2 and PP3 were used at 1 lg ml À1 based on SU6656 results. Cells, seeded at 0.15-0.4 3 10 6 cells ml À1 , were pre-treated for 30 min with inhibitors and then incubated in the absence or presence of IVIg for up to 3 days. Dimethylsulfoxide was used as solvent control for inhibitor addition in a range of 0.05-0.2% and did not exert any effect on cell proliferation and viability. The mean fluorescence intensity (MFI) is given whenever the cell line is positive for the indicated marker. ND indicates no expression for the indicated marker, corresponding to a MFI lower than five for the entire population. b Cells were seeded at 150 000 cells ml À1 and cultured for up to 7 days in the presence or absence of IVIg at 20 mg ml IgG and IgM secretion was measured in high-density culture supernatants, none indicates concentrations below ELISA detection threshold (1 ng ml
À1
).
d Among the cell lines tested, surface marker expression was found to be relatively homogeneous, such that the entire cell population expressed the indicated marker whenever it was found to be positive for it. The MFI is given in parentheses.
Western blot analysis of protein phosphorylation
Cell extracts were prepared in lysis buffer containing 20 mM Tris-HCl, pH 8.0, 137 mM NaCl, 10% (w/v) glycerol, 1% (w/v) phenylmethylsulphonylfluoride, 2 lM pepstatin A, 4 lg ml À1 aprotinin and 1 mM sodium orthovanadate (41, 42) . For each test, 20 lg of proteins were subjected to 10% SDS-PAGE, along with pre-stained standards ranging from 20 to 206 kDa (Bio-Rad Laboratories, Mississauga, Ontario, Canada). Proteins were transferred onto a Hybond ECL nitrocellulose membrane (GE Life Sciences). Mouse IgG mAbs specific for phosphorylated ERK1/2 (thr202/tyr204), p38MAPK (thr180/ tyr182), rabbit polyclonal IgG specific for phosphorylated Gab1 (tyr307 and tyr627) and Gab1, ERK1/2, phosphorylated CD32 [Fc gamma receptor FccRIIB; tyr292] and p38MAPK were used according to the manufacturer's instructions (Cell Signalling Technology, Inc.) and revealed with peroxidase-conjugated goat anti-mouse IgG or antirabbit IgG (Jackson ImmunoResearch Laboratories, Inc.) using the ECL Detection System (GE Life Sciences). As loading control experiment, the same blot was subsequently stripped using Restore Western Blot Stripping Buffer (Pierce Biotechnology, Rockford, IL, USA) and then probed with a polyclonal rabbit anti-actin antibody (Sigma Canada, Oakville, Ontario, Canada) whose binding was revealed with peroxidaseconjugated goat anti-rabbit IgG as described above.
Results
IVIg reduces expansion while increasing secretion of CD40-activated human B cells
Our previous observations that IVIg modulates CD40-activated human B cells were done in conditions of high CD40 interaction, which promote activation of naive CD27 À B cells (28, 35) . We thus wanted to examine whether memory CD27 + B cell physiology was also influenced by IVIg treatment in low CD40 conditions (36) . Purified CD19 + (Fig. 1A  and C ) and sorted CD27 + and CD27 À (Fig. 1B and D ) B cells were stimulated, as indicated, in conditions of either high or low levels of CD40-CD154 interaction in the presence of IL-4 alone or in the presence of IL-2 and IL-10, respectively. IVIg or BSA (control) were added at 10 mg ml À1 and maintained for 14 days (Fig. 1) . These high and low stimulation conditions enabled to stimulate naive only as well as both naive and memory B cell proliferation, respectively (36). As previously described (28), BSA did neither alter expansion nor secretion when compared with B cells unexposed to BSA (data not shown). IVIg reduced, by ;4-fold, the proliferation of CD19 + B cells in both condition interactions (Fig. 1A) . The effect of IVIg on proliferation was almost undetectable for sorted CD27 + and CD27 À B cells when stimulated with a low level of CD40-CD154 interaction (Fig. 1B) , in comparison to the unsorted CD19 + cells in the same conditions. The absence of of IVIg-induced inhibition on proliferation when naive and memory B cells were treated separately suggests that interactions between these cells could be involved in this IVIg effect. As previously reported, the secretion of IgG, but not IgM, was significantly increased by at least 2-fold for all tested populations (Fig. 1C and D) . Furthermore, the IVIg enhancement of IgG secretion was more noticeable in conditions supporting high differentiation, namely low CD40-CD154 interaction. These results indicated that IVIg treatment enhanced terminal differentiation of the majority of both naive and memory B cell populations.
Proliferation and differentiation of DB cells, a memory-like cell line, is modulated by IVIg treatment
The analysis of IVIg-induced phosphorylation of proteins in human B cells remains challenging, because of the presence of heterogeneous populations of both naive and memory B cells (26) and the fact that only a fraction of these cells respond to such treatment (28) . To simplify our investigations, we thus worked at identifying a suitable model by screening a panel of nine well-characterized human B cell lines exposed to IVIg. Briefly, we treated RL and DB cells expressing IgM or IgG, respectively, Daudi, Namalwa, Raji, Ramos and SKW6.4, simultaneously expressing IgD and IgM, as well as SUP-B15 and RPMI-8226, both negative for surface Ig [data not shown and (29, 30)], with 20 mg ml
À1
of IVIg. This concentration roughly corresponds to the blood levels obtained following a high dosage IVIg therapy (2) . The effects of IVIg were monitored by comparing the generation time (T gen ) of treated cells to that of untreated cells (Table 1) . Overall, we found that the proliferation of DB cells + B cells (C) and CD27 + and CD27 À B cells (D) were determined over a 24-h period. IVIg increases in secretion were significant for low (***P < 0.001) and high conditions (*P < 0.01) for IgG and only for CD27
+ cells for IgM (**P < 0.005). Errors bars, can be smaller than symbols.
was the one mostly impeded by IVIg, as revealed by an average 2.9-fold increase in their T gen (Table 1) .
DB cells are IgG + CD27 + CD38 + , a phenotype that is typical of memory B cells (43) . These cells also showed an elevated expression of surface CD32, also known as the FccRIIB (5) (Fig. 2A) . To further investigate the effects of IVIg on this cell line, DB cells were treated with IVIg or BSA at 5, 10, 15 and 20 mg ml
, and their expansion and viability were determined over a 7-day period (Fig. 2C) . BSA had no influence on DB cell proliferation or viability, whereas the effect of IVIg on proliferation was concentration dependent. Additionally, cell viability was not affected by IVIg treatment (>90%, data not shown), suggesting that the marked effect of IVIg on DB cells was not mainly attributable to increased cell death (28) but rather to a reduction or a delay in growth likely involving increased differentiation.
The IgG secretion rate of DB cells was evaluated following a 5-day treatment in the presence or absence of 10 mg ml
of IVIg or BSA (Fig. 2) . Again, BSA had no effect, while IgG secretion rate was increased by 4-fold by IVIg treatment, indicating that differentiation of DB cells was modulated by IVIg, as previously observed for human B cells (Fig. 1) . Such an enhanced secretion, combined to a reduced proliferation, validate DB cells as an appropriate model of IVIg-induced human B cell modulation (28) Table 2 ). Among this panel of inhibitors, only PD98059 and PP2, both targeting ERK1/2, inhibited, by 80-85%, the effects of IVIg on DB cell proliferation (Table 2) .
To confirm that IVIg treatment induces ERK1/2 activity in DB cells, protein extracts prepared from untreated and IVIg-treated DB cells were analyzed by immunoblotting to probe ERK1/2, p38MAPK and the adaptor protein Gab1 phosphorylation status (Fig. 3A) . Goat anti-human IgG , as indicated. Viable cell numbers were determined using Trypan Blue dye exclusion. Error bars can be smaller than symbols. Data are representative of three independent experiments. (C) DB cells were treated for 5 days with or without IVIg or BSA at 10mg ml À1 and extensively washed to reduce traces of IVIg to a minimum. IgG secretion was determined over a 22-h period. Differences between controls (untreated and BSA treated) and IVIgtreated cells were significant (P < 0.001). Data are representative of three independent experiments. F(ab#) 2 (anti-c) at 10 lg ml À1 was used as a positive control for BCR activation as reported elsewhere (38) . DB cell proliferation was partially inhibited by anti-c treatment, while IVIg treatment led to responses comparable to those reported in Fig. 2 (data not shown) . The binding of surface IgGs on DB cells by anti-c did induce intracellular phosphorylation of Gab1, as reported for human B cell lines (51) and of ERK1/2, as for human B cells (52) . As for antic, IVIg treatment resulted in Gab1 phosphorylation at its tyrosine 307, whereas the level of phospho-ERK1/2, p42 and p44 proteins appeared higher (Fig. 3A) . No variation was, however, observed for p38MAPK phosphorylation with IVIg and anti-c treatments. These results show that IVIg modulation of DB cells indeed involves phosphorylation of ERK1/2 and Gab1.
Since sustained ERK1/2 phosphorylation is linked to IgG but not IgM binding on human B cells (52), we then compared intracellular phosphorylation of DB cells with that of Daudi and SKW6.4 cells, which both expressed IgD and IgM, and that of RPMI-8226 cells lacking surface Igs (Fig.  3B) (Fig. 3) Pfeiffer and DB cells show phospho-ERK1/2 following treatment with low doses of IVIg
To verify whether IVIg induction of ERK1/2 phosphorylation was restricted by unique features specific for DB cells, we treated Pfeiffer cells with IVIg. Though originating from DLBCL and expressing IgG, like DB cells do (30) , Pfeiffer cells were found to express IgG 4 using a V H 3 gene segment, while DB cells expressed IgG 3 using a V H 4 gene segment (data not shown). Pfeiffer cell proliferation was reduced by only 16% in the presence of 10 mg ml À1 IVIg. However, IVIg induction of ERK1/2 phosphorylation was detectable using as little as 0.05 mg ml À1 IVIg, which contrasted with the 0.5 mg ml
concentration needed to observe similar effects in DB cells ( Fig. 4A and C ). DB cells expressed high level of FccRIIB (CD32 in Fig.  2A ) in comparison to Pfeiffer cells (data not shown). To verify whether ERK1/2 phosphorylation in response to IVIg was dependent on FccRIIB, we used an Ig preparation designed for intramuscular use (IMIg), containing ;20% IgG aggregates, which were recently reported as potent CD32 activators (39) . IMIg and IVIg were used at the same concentration of 5 mg ml À1 total IgG ( Fig. 4B and D) . Compared with IVIg, IMIg was found to be a less potent inducer of ERK1/2 phosphorylation in DB and Pfeiffer cells, and this reduced induction of phosphorylation cannot be attributed to a lower concentration of monomeric IgG (;4 mg ml À1 ), on the basis of the results presented in Fig. 4 (panels A and C). Since the IgG reactivities contained in IVIg and IMIg might have been different, we further investigated the level of ERK1/2 phosphorylation in DB cells, using heattreated IVIg (46% aggregates) and purified human IgG (25% aggregates) compared with that of untreated preparations. These sources of human IgG were used at a final concentration of 1 mg ml À1 IgG (Fig. 4E) . Once again, induction of ERK1/2 phosphorylation was reduced when DB cells were incubated with preparations containing IgG aggregates. In contrast, a preparation of essentially native, purified IgG such as IVIg potently stimulated ERK1/2 phosphorylation. Finally, IVIg did not induce phosphorylation of CD32 on its immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic tail (Fig. 4F) , while IMIg, containing aggregated IgG, did, as expected (53) . Once more, ERK1/2 phosphorylation was lower when cells were treated with IMIg compared with IVIg used at identical concentrations. Worthy of note, IMIg, purified IgG and IVIg all exhibited a similar level of reactivity against human IgG F(ab#) 2 fragments (data not shown) and can all bind to human surface IgG. IgG content was identical in all treatments, indicating that aggregated IgG did not contribute to IVIg-enhanced ERK1/2 phosphorylation (Fig. 4) . 
IVIg-treated DB cells and normal human B cells showed up to 5-fold increases in intracellular p-ERK1/2
Intracellular flow cytometry analyses were performed using untreated and IVIg-treated DB cells to quantify the intracellular level of p-ERK1/2 and compare it to p-Akt, p-p38, p-SAPK/JNK and total p-tyr (Fig. 5A) . Overall, ERK1/2 phosphorylation was 3-to 5-fold higher (4.0 6 0.8; n = 4) in IVIg-treated cells, which supported previous data presented above (Figs 3 and 4) . No variation was observed in the level of p38 or SAPK/JNK phosphorylation, while p-Akt was increased by ;2-fold (2.3 6 0.3; n = 2). In contrast, the total phosphotyrosine content was decreased by ;25% (22 6 4%; n = 2) when DB cells were treated with IVIg, which could be related to a decrease in overall cell activation resulting from reduced proliferation (Fig. 2) . Additionally, a higher proportion of larger cells [;4-fold (4.3 6 1.2); n = 2] were detected in IVIg-treated DB cells, which is also consistent with increased differentiation (Fig. 5A) .
Finally, based on all the above observations, we went back to normal human B cells to measure IVIg-induced phosphorylation of ERK1/2 using surface and intracellular staining to differentially gate IgG + cells (Fig. 5B ). To this purpose, purified B cells were first activated in vitro using the high stimulation conditions as reported in Fig. 1(A) and their phosphorylation content was exhausted immediately before being treated with IVIg. Overall, a 2-fold (2.2 6 0.4; n = 3) increase in phosphorylated ERK1/2 was observed within the IgG + cell population after a 2-h IVIg treatment. No such variation was observed in the total CD19
+ population, indicating a bias for IgG + cells. These results are in agreement with several results presented above and further connect IVIginduced ERK1/2 phosphorylation with human IgG + B cells, as was observed in the IgG + DB cell line (Fig. 5 ).
Discussion
Patients suffering from autoimmune diseases can receive doses of up to 2.0 g kg À1 of IVIg, leading to serum IVIg levels of 5-25 mg ml À1 (54, 55) . In this study, we first showed that among a panel of nine human B cell lines studied, DB cells responded to IVIg at the above clinical concentrations in the same way as we had previously reported for normal human B cells (28) . DB cells, which are IgG + CD27 + CD38 + , show striking similarities with memory B cells. DB cells are EBV negative (56) , thus ruling out EBV-related dysfunction of their BCR (57) . Indeed, their BCR appeared functional, based on their response to anti-c stimulation (Fig. 3) , which resulted in increased ERK1/2 phosphorylation, as reported for normal human B cells (52) . Such an increased ERK1/2 phosphorylation suggests that apoptosis could contribute to the IVIg-induced reduction in proliferation (58); however, we did not observe changes in cell viability that could be directly attributed to IVIg treatment. Nonetheless, inhibition of DB cell proliferation by IVIg might thus be considered as a possible strategy in the prevention of tumor spreading, as proposed by another group (59) .
Studies on the mechanisms of action of IVIg have highlighted a crucial role for FccRIIB, a low-affinity IgG receptor [reviewed in ref. (4)] whose inhibitory activity can proceed through ITIM-dependent or -independent signaling pathways (60, 61) . In the presence of antigen-IgG complexes, FccRIIB co-clusters with the BCR, causing Lyn to phosphorylate its ITIM and the ensuing recruitment of Src homology 2-domain-containing inositol polyphosphate 5#-phosphatase (SHIP) that dephosphorylates PI-3,4,5,-P 3 . Depletion of PI-3,4,5,-P 3 impairs the ability of the BCR to activate Akt and Bruton tyrosine kinase (Btk) [reviewed in ref. (61)]. Coclustering of BCR and FccRIIB can also induce Gab1 dephosphorylation and its dissociation from PI3K (51). Additionally, FccRIIB and FcRH4, another inhibitory Fc receptor expressed on memory B cells (62) , inhibit ERK activation and Ca 2+ influx following their co-ligation to the BCR (63). On the other hand, anti-idiotypic antibodies present in IVIg are also hypothesized to participate, through direct binding to the BCR, in the re-establishment of the idiotypic network by stimulating so-called 'good regulator' B cells (9, 10, 13, 64) .
However, studies with human peripheral B cells are technically challenging, and experimental data suggesting the direct modulation of B cell signal transduction by IVIg are still missing. In the present study, we have circumvented these limitations by using the DB cell line and pharmaceutical inhibitors to target various intermediates involved in BCR signaling. The growth inhibitory effect of IVIg was reduced by 80 and 85% following pre-treatment with PP2 and PD98059, respectively. Interestingly, both of these agents can interfere with ERK phosphorylation (44, 47, 48) . Subsequently, IVIg-induced phosphorylation of ERK1/2, Gab1 and Akt, which altogether are related to BCR signal transduction (19) , may thus represent a possible link between IVIg and IgG. One may, however, question the relevance of such an increase in phosphorylated ERK1/2, while no parallel changes are observed in p38 and SAPK/JNK phosphorylation, even though both of these signal transducers operate at the same level of BCR signal integration (19 (66) , the effects of IVIg that are related to the BCR could have been overlooked in these cell lines. IVIg signaling in monocytes, which respond through FccRIIB independently of SHIP-1, SHP-1 and Btk (67, 68) , was found to be different from that reported for FccRIIB in B cells (61) , which rely upon these signal transducers in their response to IVIg. In our assays, IVIg did not induce phosphorylation of FccRIIB on its ITIM cytoplasmic region, while IMIg did, indicating that the IVIg-induced modulation of ERK1/2 phosphorylation was not dependent on this pathway.
Nevertheless, in the present study, we observed increased phosphorylation of ERK1/2, Gab1 and Akt following IVIg treatment of DB cells. These observations indicate that such IVIg modulation of DB cells is most likely not mediated through the direct binding of an inhibitory IgG receptor such as FccRIIB (CD32) or even the Fc receptor-like protein 5, recently shown to inhibit BCR signaling through its cytoplasmic tail (69) . This conclusion is in accordance with observations done by Mazer's group for human tonsillar B cells (70) . Furthermore, experiments reported in the present work with IgG preparations containing 20-46% IgG aggregates, which are known to promote CD32 activation (39), did not induce but rather reduced ERK1/2 phosphorylation.
Overall, our study demonstrates for the first time that IVIg binding to human B cells enhances phosphorylation of Gab1, Akt and ERK1/2 and suggests that these events could proceed through BCR signaling. Furthermore, the binding of IVIg to surface IgG could be related to the fact that IVIg contains natural antibodies against human IgG F(ab#) 2 fragment (28, 71) . These observations bear relevance to the modulation of autoimmunity by IVIg owing to its reactivity against surface Ig as proposed by others (9, 10, 72) . Whether BCR binding by IVIg or co-clustering of several BCRs can influence proliferation and secretion in normal human B cells (28, 73) remains to be investigated.
We had previously considered that the heterogeneity of peripheral B cells implied that different populations were distinctly modulated by IVIg and that this heterogeneity might contribute to the differential effects of IVIg on proliferation and differentiation. Here we observed that the effects of IVIg on proliferation and differentiation can simultaneously occur on a homogeneous IgG + cell population, as previously observed on a more heterogeneous population of human B cells. We did not detect activation of the same signaling pathways when IgM + cells were exposed to IVIg, but this could be related to the faster turnover of phospho-ERK when IgM, instead of IgG, was activated, as reported elsewhere (52) . Finally, similar observations were made in human IgG + CD40-activated B cells. It was recently showed that IVIg treatment generates an increase in the frequency of immature plasma cells in the blood of patients suffering from autoimmune diseases (74) . Worthy of note, this increase in the frequency of blood plasma cells correlates with recovery of neurological function in patients with Guillain-Barré syndrome, suggesting a displacement of «bad» autoreactive plasma cells by «harmless» emerging plasma cells. Our observations indicating that IVIg upregulates human B cell differentiation toward Ig-secreting and CD138
+ cells are in agreement with these clinical observations.
In summary, our results indicate that the ERK pathway is an important mediator of IVIg signaling in human B cells. IVIg activation of this pathway might result in the modulation of proliferation and Ig secretion by human B cells through the possible binding of surface receptors such as the BCR or other receptors proceeding through this pathway, such as activating FccRs (75) . Finally, this study opens new avenues for further investigations on the immunomodulation of autoreactive human B cells by IVIg and its contribution to the restoration of homeostasis in patients with autoimmune diseases. 2-oxo-3-(4,5,6,7-tetrahydro-1H-indol-2-ylmethylene)-2,3-dihydro-1H-indole-5-sulfonic acid dimethylamide
